Stephens Consulting’s Cytokinetics CYTK Stock Holding History

Stephens Consulting’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30	Closed	-$1.21K	–	1402
2025 Q1	$1.21K	Buy	+30	New	+$1.38K	﹤0.01%	566

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Stephens Consulting's CYTK Position: Q2 2025 in Review

Stephens Consulting sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 30 shares — an estimated $1.21K sold.

Stephens Consulting first reported a position in CYTK in Q1 2025 and held it in 1 quarter. The position peaked at $1.21K in Q1 2025. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Stephens Consulting reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 30 Cytokinetics shares in Q2 2025, an estimated $1.21K.
Stephens Consulting first reported a position in Cytokinetics in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Cytokinetics position peaked at $1.21K in Q1 2025.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.